Regeneron Pharma's (REGN) Latest Dupixent Data Can Add $12/sh, Drug Peak Sales are $14B Across All Indications - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $756.00 price target on Regeneron Pharma (NASDAQ: REGN), following recently ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
